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Objectives. Poor results have been reported following infrainguinal reconstructions using heterogenous grafts. The
objective of this study was to assess the use of bovine mesenteric vein (ProCol) graft in patients with critical limb ischaemia
(CLI), tissue loss/infection and no autologous vein available for reconstruction.
Methods. Prospective analysis of 32 patients with CLI and tissue loss/infection, in whom reconstruction with ProCol was
undertaken between October 1999 and May 2002.
Results. The primary patency rate was 16% at 1 month. After thrombectomy, the secondary patency rate was 50% at 1
month and 26% at 14 months. No graft infections were seen. Aneurysmal dilatation of the graft occurred in 2 (6%). Limb
salvage at 14 months was 47%.
Conclusion. In patients with critical limb ischaemia, tissue loss/infection and no available vein, the ProCol graft may be an
alternative. However, primary patency is a problem. In situations without tissue loss/infection, where the risk of graft
infection is less, prosthetic material may be a better alternative.
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Introduction
An increasing number of elderly patients present with
critical ischaemia, and no available autologous vein. If
extensive tissue loss and/or severe infection are present
as well, amputation may be the only alternative. In some
situations, using a biological material seems reasonable,
as the heterografts may be more resistant to infection
than prosthetic grafts. Disappointing results have been
published with previous heterografts.1 However, graft
harvesting and preservation methods may have
improved during the past decade. We have used a
glutaraldehyde tanned bovine mesenteric vein graft
(Procol, Hancock Jaffe Laboratories, Irvine, CA, USA) in
such difficult situations. To date there have been no
published middle or long-term results with regard to the
use of the ProCol graft in infrainguinal reconstruction.
Our experiences with this graft are presented.
Materials and Methods
Thirty-two patients, 20 (63%) males, 12 (38) females,
median age 69.8 years, (range 42–82) underwent
infrainguinal arterial reconstruction with a ProCol
graft between October 1999 and May 2002. All patients
had Fontaine Class III or IV limb ischaemia, with tissue
loss and/or infection. Nineteen (59%) had previously
undergone infrainguinal reconstructive surgery and
17 (53%) a radiological intervention.
Preoperative investigations had demonstrated
satisfactory distal run-off in 18 (56%) patients, and
the operation was attempted in order to avoid an
otherwise imminent amputation. Fourteen patients
(44%) were diabetic. Other risk factors included
hypertension in 17 (53%) and smoking in 16 (50%).
All patients had preoperative duplex Doppler vein
mapping of arms and legs performed. A usable
segment of less than 15 cm was seen in 21 (66%), and
no usable veins in 11 (34%).
Four grafts (12%) were anastomosed to the supra-
genicular popliteal artery, six (19%) to the infrageni-
cular popliteal artery, 19 (60%) to crural vessels and
three (9%) to a pedal artery. No patient had more than
one patent calf vessel. ProCol alone was used in nine
(28%) cases, and combined with a short segment of
autologous vein for the distal anastomosis in 22 (69%).
In one case (3%), the proximal anastomosis was
sutured to a previous Dacron prosthesis. Intraopera-
tive flow measurements were recorded routinely to
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detect technical errors and to determine whether grafts
should be re-explored if postoperative thrombosis
occurred.
Postoperatively, all patients were heparinised intra-
venously (15,000 units/24 h). The 24 (75%) patients
with a patent graft postoperatively were anticoagu-
lated with coumadine. All patients were reviewed at 6
weeks, 6 months, 1 year, and then annually. The review
included patient interview, clinical examination and
duplex ultrasound scan.
Results
One patient (3%) died within 30 days from a myocardial
infarction. Other complications included haematoma
formation in four (12%), and superficial wound
infection in one (3%). No graft infections were seen.
In 19 (59%) cases, thrombosis occurred on the day of
operation and only five (16%) grafts remained patent,
without intervention, at 1 month. Nineteen patients
(41%) were re-explored and thrombectomy was
successful in 13 (68%) cases. In eight (25%) the
situation was deemed hopeless due to poor intrao-
perative graft flow, and an amputation was performed
without re-exploration.
The secondary patency rate was 50% at 1 month and
at 14 months was 8/31 (26%). Secondary amputation was
performed in nine (28%) patients. The total amputation
rate at 14 months was 17/32 (53%). Two grafts (6%) were
reoperated during follow-up for aneurysmal dilatation.
Limb salvage at 1 year was 15/32 (47%). Fig. 1 shows
the actuarial intervention free survival.
Discussion
A recent study in this journal reported a primary
patency rate of 0% in infrainguinal reconstruction
using ProCol grafts.1 The report was based on six
patients. The authors commented on their results as
being ‘very disappointing’, and did not recommend
the use of ProCol graft for arterial reconstruction.
Autologous vein is unavailable in up to 30% of the
patients2 and the number may be increasing due to the
aging patient population with more co-morbidities.
An optimal substitute to autologous vein has not been
found. The initial results using human umbilical vein
allograft in the 1970s were promising.3 However, graft
degradation and aneurysmal dilatation are proble-
matic,4 and the graft has fallen out of favour.5
Heterografts have been available since 1963, but
most of them have been abandoned due to poor
long-term results.6,7 Recently, Farber et al.5 reported
their results using cryopreserved saphenous vein
homografts (Cryograft) in infrainguinal revasculariza-
tion. In recent years, there have been some advances in
the harvesting and preservation of heterografts. The
theoretical biological advantages of the ProCol include
a well-preserved media layer, a large extracellular
matrix and three-dimensional compliance.
We have used ProCol grafts in extreme situations in
vascular access surgery (to date 50 cases), and in 36
infrainguinal reconstructions, of which longer term
results have been obtained in 32 so far. In the study by
Farber et al.,5 Cryograft was initially used instead of
alternative autologous vein. However, poor 1-year
primary patency of 30% forced the team to change
their policy. We have only used ProCol in patients with
a combination of critical ischaemia, tissue loss/
infection and no available vein (Grade III according
to Rutherford’s classification). In these situations,
primary amputation would have been the alternative,
as infection precludes the use of prosthetic grafts due
to the risk of graft infection. In our series, no graft
infections were seen. There was one (3%) superficial
wound infection. Martin et al.8 and Walker et al.9 have
used cryopreserved saphenous vein homografts as a
last resort in critical ischaemia with a high risk of
infection, as the biograft does not seem to be as
susceptible to infection.
Kovalic et al.1 reported a primary patency of 0% at 3
months. In our series, the primary patency was also
poor: 16% at 1 month. However, two thirds of the
patients underwent surgical graft thrombectomy
during initial hospitalisation. The thrombus material
observed was not adherent to the graft wall, and easy
to remove. Thrombectomy was successful in two
thirds of cases but was not successful in cases with
poor outflow. We have tried to overcome the problem
by aggressive antithrombolytic therapy and intrave-
nous heparinisation. Kalangos et al.10 have published
results using ProCol as systemic pulmonary shuntFig. 1. Kaplan-Meier for primary patency.
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without anticoagulation or antithrombolytics, but
these results were obtained in a paediatric population.
In the series of Farber et al.,5 anticoagulation did not
improve the patency of the Cryograft. Attention to the
smallest technical detail intraoperatively is important.
The graft increases its length by up to 15%, when the
proximal anastomosis is performed and flow is
allowed to enter the graft. The graft also requires
repeated heparinisation during the procedure.
Secondary patency rates with infragenicular PTFE
grafts are in the order of 21–48% at 2 years.11 – 14 Farber
et al.5 reported a secondary patency of 26% at 2 year
using Cryograft, which is the same as in our study,
achieved in the extreme clinical setting of critical
ischaemia, tissue loss and/or infection. In our study
population, the only other available option for the
patients would have been primary amputation. The
limb salvage rate was 47% in our series, which is less
than the 70% at 2 years published by Farber et al.5 and
Harris et al.15 In our series, the indication for operation
was uniformly Grade III ischaemia. Carpenter et al.16
reported a limb salvage rate of 42% at 1 year, which is
similar to ours.
We conclude that ProCol graft has poor primary
patency. Secondary patency is somewhat better and its
use may be considered in high-risk reconstructions
when no autologous vein is available. In situations
without infection, prosthetics may offer a better
alternative.
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